Evidence map›Paper›PMID 25926293›Full record

ArticleLung2015

Intrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Marker in Pulmonary Arterial Hypertension.

Jasmin Wellbrock, Lars Harbaum, Hauke Stamm, Jan K Hennigs, Björn Schulz, Hans Klose, Carsten Bokemeyer, Walter Fiedler, Nicole Lüneburg

Abstract read
PubMed Publisher
In one paragraph

Article in Lung, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. GREM1 signaling in cancer: tumor promotor and suppressor?Journal of cell communication and signaling · 2023
    Article
  3. Review
  4. Article
  5. Article
  6. Emerging therapeutics in pulmonary hypertension.American journal of physiology. Lung cellular and molecular physiology · 2018
    Review
  7. Article
  8. Gremlin-1 Concentrations Are Correlated with the Severity of Knee Osteoarthritis.Medical science monitor : international medical journal of experimental and clinical research · 2016
    Article
  9. Article
  10. Article
  11. Overexpression of Gremlin promotes non-small cell lung cancer progression.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jasmin WellbrockDepartment of Hematology, Oncology and Stem Cell Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, j.wellbrock@uke.de.
Lars Harbaum
Hauke Stamm
Jan K Hennigs
Björn Schulz
Hans Klose
Carsten Bokemeyer
Walter Fiedler
Nicole Lüneburg
Universität Hamburg · DEUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gremlin-1, an intrinsic antagonist of bone morphogenetic protein (BMP) signaling, has been implicated in the pathophysiology of pulmonary arterial hypertension (PAH). However, it is unknown whether gremlin-1 can be detected in the circulation of PAH patients and whether it is associated with patients' functional status and outcome. With a mean level of 242 ± 24 ng/ml, gremlin-1 levels of 31 PAH patients were significantly elevated compared to 151 ± 18 ng/ml in 15 age- and gender-matched healthy subject (p = 0.016). In PAH patients, increasing gremlin-1 levels correlated with N-terminal prohormone of brain natriuretic peptide levels (r = 0.608, p < 0.001) and inversely with the 6-minute walking distance (r = -0.412, p = 0.029). Furthermore, gremlin-1 significantly stratified survival in PAH patients (p = 0.015). Gremlin-1 may represent a new biomarker for PAH which can be linked directly to the underlying pathomechanism. Elevated levels of gremlin-1 are associated with patients' functional status and survival, thus gremlin-1 neutralization could represent a potential therapeutic strategy to increase BMPR2 signaling.

Indexed as

AgedBiomarkersBone Morphogenetic ProteinsCase-Control StudiesExercise TestFemaleGlomerular Filtration RateHumansHypertension, PulmonaryIntercellular Signaling Peptides and ProteinsMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPulmonary ArterySignal TransductionBiomarkersBone Morphogenetic ProteinsGREM1 protein, humanIntercellular Signaling Peptides and ProteinsNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Identifiers

PMID25926293
OpenAlexW1986825521

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.